Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 83.3%Moderate 1 · 16.7%High 0 · 0%

Oral long‐chain omega‐3 PUFAs vs placebo or no treatment

Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea

Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with placebo or no treatment (low certainty).

1 finding from 1 review

Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1785 participants
Low

Oral long‐chain omega‐3 PUFAs vs placebo or no treatment

Change in ocular surface staining at 1‐month (with actual · people with dry eyea

Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in ocular surface staining at 1‐month (with actual compared with placebo or no treatment (low certainty).

1 finding from 1 review

Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes only
MD 0.1
4 studies · 681 participants
Low

Oral long‐chain omega‐3 PUFAs vs placebo or no treatment

Aqueous tear production · people with dry eyea

Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes only
MD 0.68
7 studies · 1730 participants
Moderate

Oral long‐chain omega‐3 PUFAs vs placebo or no treatment

Tear film stability · people with dry eyea

1 finding from 1 review

Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1640 participants
Low

Oral long‐chain omega‐3 PUFAs vs placebo or no treatment

Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea

Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in tear osmolarity (measured in mOsmol/L, with reductions in… compared with placebo or no treatment (low certainty).

1 finding from 1 review

Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Low

Oral long‐chain omega‐3 PUFAs vs placebo or no treatment

Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea

1 finding from 1 review

Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 719 participants
Low